Treatment of acute myelogenous leukemia with outpatient azacitidine
作者： Nimit Sudan , James M. Rossetti , Richard K. Shadduck , Joan Latsko , John A. Lech
DOI: 10.1002/CNCR.22204
关键词:
摘要: Patients older than 55 years of age with acute myelogenous leuke-mia (AML) are less likely to achieve complete remission and more experi-ence toxicity conventional induction chemotherapy younger patients.Azacitidine administered in the outpatient setting is well tolerated can inducecomplete hematological patients myelodysplastic syndromes(MDS). At higher doses, azacitidine has activity AML.
researchgate.net 
sci-hub.se 参考文章(19)
Lee Ej, Gallagher R, Schiffer Ca, Hogge De, Low dose 5-azacytidine is ineffective for remission induction in patients with acute myeloid leukemia. Leukemia. ,vol. 4, pp. 835- 838 ,(1990)
Elaine S. Jaffe, Pathology and Genetics: Tumours of Haematopoietic and Lymphoid Tissues ,(2003)
F. Creusot, G. Acs, J.K. Christman, Inhibition of DNA methyltransferase and induction of Friend erythroleukemia cell differentiation by 5-azacytidine and 5-aza-2'-deoxycytidine. Journal of Biological Chemistry. ,vol. 257, pp. 2041- 2048 ,(1982) , 10.1016/S0021-9258(19)68144-5
B Löwenberg, R Zittoun, H Kerkhofs, U Jehn, J Abels, L Debusscher, C Cauchie, M Peetermans, G Solbu, S Suciu, On the value of intensive remission-induction chemotherapy in elderly patients of 65+ years with acute myeloid leukemia: a randomized phase III study of the European Organization for Research and Treatment of Cancer Leukemia Group. Journal of Clinical Oncology. ,vol. 7, pp. 1268- 1274 ,(1989) , 10.1200/JCO.1989.7.9.1268
B D Cheson, P A Cassileth, D R Head, C A Schiffer, J M Bennett, C D Bloomfield, R Brunning, R P Gale, M R Grever, M J Keating, Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. Journal of Clinical Oncology. ,vol. 8, pp. 813- 819 ,(1990) , 10.1200/JCO.1990.8.5.813
Lee R. Silverman, Andrew J. Phipps, Andy Montgomery, Soledad Fernandez, Tomonori Tsukahara, Lee Ratner, Michael D. Lairmore, In vivo analysis of replication and immunogenicity of proviral clones of human T-lymphotropic virus type 1 with selective envelope surface-unit mutations Blood. ,vol. 106, pp. 3602- 3608 ,(2005) , 10.1182/BLOOD-2005-03-1076
Judith K. CHRISTMAN, Peter PRICE, Lauri PEDRINAN, George ACS, Correlation between hypomethylation of DNA and expression of globin genes in Friend erythroleukemia cells. FEBS Journal. ,vol. 81, pp. 53- 61 ,(1977) , 10.1111/J.1432-1033.1977.TB11926.X
H. R. Gralnick, H. R. Gralnick, C. Sultan, J. M. Bennett, M. T. Daniel, D. Catovsky, G. Flandrin, D. A. G. Galton, Proposals for the classification of the myelodysplastic syndromes. British Journal of Haematology. ,vol. 51, pp. 189- 199 ,(1982) , 10.1111/J.1365-2141.1982.TB02771.X
J. H. Saiki, K. B. McCredie, T. J. Vietti, J. S. Hewlett, F. S. Morrison, J. J. Costanzi, W. J. Stuckey, J. Whitecar, B. Hoogstraten, 5-azacytidine in acute leukemia Cancer. ,vol. 42, pp. 2111- 2114 ,(1978) , 10.1002/1097-0142(197811)42:5<2111::AID-CNCR2820420505>3.0.CO;2-I
Lewis R. Silverman, Erin P. Demakos, Bercedis L. Peterson, Alice B. Kornblith, Jimmie C. Holland, Rosalie Odchimar-Reissig, Richard M. Stone, Douglas Nelson, Bayard L. Powell, Carlos M. DeCastro, John Ellerton, Richard A. Larson, Charles A. Schiffer, James F. Holland, Randomized Controlled Trial of Azacitidine in Patients With the Myelodysplastic Syndrome: A Study of the Cancer and Leukemia Group B Journal of Clinical Oncology. ,vol. 20, pp. 2429- 2440 ,(2002) , 10.1200/JCO.2002.04.117